drugset
drugset / Trial / NCT04201496

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

NCT04201496 ↗

Phase 1 Completed 34 enrolled Ananda Basu, MD DexCom, Inc. · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabTandem Diabetes Care, Inc. · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the safety and efficacy of combining SGLT2 inhibitors with closed loop control (CLC).

Timeline

Start
2020-02-24
Primary completion
2021-09-07
Completion
2021-09-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 5 mg —
Subject Empagliflozin Small molecule 10 mg —

Indications

type 1 diabetes mellitus